Eli Lilly Forecasts Profit, Revenue Drop In 2014
Eli Lilly expects a sharp drop in both earnings and revenue next year, as the drug developer deals with the loss of patents protecting two more key drugs from cheaper generic competition.
This premium content is reserved for Daily Business Review subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now